Plans to roll out a "revolutionary" breast cancer drug across the UK are "a huge step forward", according to health campaigners.
Kadcyla will be available on the cancer drugs fund, a move which will make "a significant difference" to breast cancer sufferers who have stopped responding to chemo, according to Dr Caitlin Palframan.
Kadcyla has been shown to extend life by up to six months in HER2-positive secondary breast cancer patients, and with more manageable side effects than alternative drugs.
It has the potential to provide women with a better quality of life in their final months than existing treatments, which could make a significant difference.
A thousand women die from metastatic, or secondary, breast cancer every month in the UK and this treatment has the potential to provide some of them not only with additional time, but importantly, quality time to spend with their friends and families.
More top news
The animal charity has taken in 33% more abandoned animals in 2014, officials say.
Some 26% of online shoppers complained of poor delivery service.
A man thought to be the first person in the world to recover from complete severing of the spinal nerves is able to walk again after surgery